In this article, recent advances in the identification of selective cholecystokinin B (CCKB)b (gastrin) receptor antagonists will be briefly reviewed and their possible therapeutic role in the treatment of gastric secretory disorders briefly discussed. To address these questions, it is important first to have a general understanding of the role of CCK receptors in different processes as well as to understand the recent advances in classifying receptors that mediate the action of CCK and gastrin-related peptides. These areas will be briefly reviewed first.
INTRODUCTION
In this article, recent advances in the identification of selective cholecystokinin B (CCKB)b (gastrin) receptor antagonists will be briefly reviewed and their possible therapeutic role in the treatment of gastric secretory disorders briefly discussed. To address these questions, it is important first to have a general understanding of the role of CCK receptors in different processes as well as to understand the recent advances in classifying receptors that mediate the action of CCK and gastrin-related peptides. These areas will be briefly reviewed first.
I. CLASSIFICATION OF CCK RECEPTORS AND THEIR ROLES IN DIFFERENT PHYSIOLOGICAL PROCESSES Cholecystokinin (CCK) structurally closely resembles gastrin at its carboxyl terminal, which is the biological active portion of the peptide [1] [2] [3] [4] [5] [6] [7] . Both peptides end in the pentapeptide gly-trp-met-asp-phe-NH2 [2, 8] . However, they differ in the presence or absence of a sulfated tyrosine in position 7 from the carboxy-terminal phenyalanine amide. The presence of this group is the primary determinant of high affinity to cause the classical actions of CCK of stimulating pancreatic secretion and gallbladder contraction [2-5, 7, 8] . Recent studies demonstrate CCK immunoreactivity is widely distributed in the central nervous system (CNS) and gastrointestinal tract (in duodenal I cells and in nerves), whereas gastrin immunoreactivity is more localized, occurring predominantly in gastric antral and duodenal G cells, with low levels in various neuroendocrine tissues (pituitary, aTo whom all correspondence should be addressed: Dr. Robert T. Jensen [6, 9] . CCK has been shown to have effects on many tissues including in the CNS (functioning as a neuromodulator, modulation of dopaminergic activity and opioid analgesia) [4, 10] ; to have growth effects (pancreas, various tumor issues) [4, 6, 11] ; to stimulate pancreatic secretion of water, electrolytes, enzymes and insulin [4, [12] [13] [14] ; to have motility effects (contraction of the gallbladder, intestinal smooth muscle, delay gastric emptying and colon motility) [4, 14, 15] ; to have gastric secretory effects (stimulate pepsinogen release, somatostatin release from D-cells, inhibit acid secretion) [4, [16] [17] [18] [19] ; and to stimulate peripheral neural effects (vagally mediated satiety) [10] . Gastrin also has been shown to cause many of the changes mediated by CCK in various tissues [10] ; to have stimulatory effect on gastric acid secretion, [9] ; to have trophic effects on the gastric mucosa, particularly on gastric enterochromaffin-like cells [9] ; to have growth stimulatory effects on numerous tumors [6, 9, 11] ; and to have CNS effects (anxiogenic action) [4, 20] .
Numerous pharmacological, biological, and now structural studies provide evidence that two classes of CCK receptors mediate the actions of CCK and gastrin: a CCKA receptor and a CCKB receptor [21] [22] [23] [24] [25] . The gene encoding the CCKA receptor has been cloned 
The structures of L-365, 260 and CI-988 are shown in Figure 1 . Data are from References [12, 23, 25, 27, 32, 44] .
from numerous species and in the human DNA sequence predicts a protein that has 428 amino acids and is a member of the G protein-coupled superfamily of receptors with seven spanning areas [21, 23] (Table 1) . The CCKB receptor, originally characterized best pharmacologically in the CNS, is now known to be the same as the gastrin receptor originally characterized in parietal cells [21, 23, 24, 26, 27] . The CCKB receptor gene has also been cloned from numerous species and the predicted human protein has 447 amino acids, 48 percent homology with the human CCKA receptor and is also a member of the G proteincoupled heptahelical superfamily [21, 23, 24, 26, 27] . The CCKA receptor and CCKB receptor differ from each other in their affinities for natural agonists ( 0.14(GP) 10, 000 [54] All data are affinities from binding studies using primarily 1251-BH-CCK-8 and are for rat pancreas (rCCKA-R), rat cortex or gastric glands (rCCKB_R) except those indicated by GP which are from guinea pig and m which are from mouse.
4. L-156, 586 15-dihydro-13, 14-anhydro-virginamycin M1 [51] .
receptors [4, 9, 23] [32] . Whereas the benzodiazepine analogue, L-364, 718, and the proglumide analogue, lorglumide (CR 1409), or the closely related compound, loxiglumide (CR 1505) , have proven to have sufficient selectivity for CCKA receptors both in vitro and in vivo to define the role of CCKA receptors in various processes, this has not been the case with the selective CCKB receptor antagonists benzodiazapine analogue, L-365, 260 or the dipeptoid compound, CI-988 (PD 134, 308) ( Table 1 ). The use of L-365, 260 has been limited by its relatively low selectivity and also its use has been limited in dogs by a reversal of the affinities of L-364, 718 and L-365, 260 for CCKB receptors, as well as the low selectivity of both antagonists in this species [21, 26, 33] . A recent study demonstrates that the difference in selectivity of L-365, 260 and L-364, 718 for human and rat CCKB receptors compared to canine CCKB receptors is due primarily to the substitution of leucine in the canine CCKB receptor for valine in the equivalent position (valine) in the 6th transmembrane region of the human CCKB receptor [26, 33] . Although CI-988 (PD-134, 308) has more than 1000-fold selectivity for CCKB receptors over CCKA receptors (Table 2) , its general usefulness has been limited by recent reports that this compound has agonist activity in some systems. PD-136, 450 (also called Cam-1189) is a dipeptoid analogue closely related to PD-134, 308, and it has been shown recently to function as a partial CCKB receptor agonist in the rat stomach for acid secretion [34] , and as a full agonist at CCKA receptor for stimulating pancreatic enzyme secretion in rats [34, 35] . Furthermore, PD-135, 158, which is also closely related to PD-134, 508 [36] , also functions as a CCKA receptor agonist in rat pancreatic acini [37] . Recent studies have demonstrated marked species differences in agonist/antagonist activity of various classes of peptide antagonists to other receptors. For example, various classes of peptide antagonists of the gastrin peptide-releasing receptors such as bombesin pseudopeptides, des Metl4 bombesin amides and alkyl amides are excellent gastrin-releasing peptide (GRP) receptor antagonists in mouse and guinea pig but function as GRP receptor agonists or partial agonists in rats [38] [39] [40] . Similarly, chimeric galanin peptide receptor antagonists such as galantide [41] and CCK peptide analogues such as CCK-(26-32)NH2, function as agonists, partial agonists and antagonists in different species [42] . These data suggest that mixed agonist/antagonist activity in different species or cell systems may be a general property of many peptide analogues that function as antagonists in some assays.
Recently, a number of different classes of highly selective non-peptide CCKB receptor antagonists have been described (Table 2, Figure 1 ). Some of these compounds have >2000-fold selectivity for CCKB receptors ( which has a selectivity of 80-280-fold for the CCKB over the CCKA receptor in different species (Table 1) and a five-to 180-fold selectivity in human transfected CCK receptors [21, 23, [43] [44] [45] [46] [47] . In general, the new CCKB receptor antagonists fall into five different chemical groups: tetronothiodin and other compounds isolated from Streptomyces, ureido-acetamide analogues, benzodiazepine analogues, glutaramic acid analogues or proglumide analogues, and pyrazolidinone analogues.
Tetronothiodin has a 19-membered ring with an alpha-acyltetronic acid and a tetrahydrothiophene moiety (Figure 1 ) and was isolated from the culture broth of Streptomyces sp. NR0489 [48, 49] . Tetronothiodin is completely different structurally from any of the other CCKB receptor antagonists (Figure 1 ) including the virginiamycin analogues L-156, 586, L-156, 587 and L-156, 588, which were also selective CCKB antagonists and were isolated from Streptomyces olivaceus [49] [50] [51] and from asperlicin, a CCKA receptor antagonist isolated from Aspergillus alliaceus [52] . A recent study [50] reports that while tetronothiodin has high affinity (affinity constant [Kj] = 3.6 nM) for CCKB receptors in the rat and a 27, 000 selectivity for rat CCKB over rat CCKA receptors (Table 2) , it has a 80-fold (KI = 280 nM) and 60-fold (Ki = 210 nM) lower affinity for mouse and human CCKB receptors (cerebral cortex) than for rat CCKB receptors. Tetronothiodin functions as a selective CCKB receptor competitive antagonist in the rat [50, 53] , however its lower affinity may limit its usefulness in humans and mice.
The newer benzodiazepine CCKB receptor antagonists include various 1, 4-benzodiazepine derivatives including ones containing an acidic group on the phenylurea portion of L-365, 260 (Figure 1 ), such as the tetrazole derivative L-368, 935 [54, 55] (Figure 1 [54, 55] . To improve the brain penetrance, a series of amidine 5-amino-1, 4-benzodiazepine analogues which had an amine-based cationic group within the benzodiazepine moiety were synthesized [56, 57] and the azabicyclonanane derivative L-740, 093 was identified and fully characterized [56, 57] (Figure 1 ). L-740, 093 has a very high affinity for guinea pig CCKB receptors (concentration causing half-maximal inhibition, [IC50]-0.10 nM) and a 16, 000-fold selectivity for CCKB over CCKA receptors (Table 2) . L-740, 093 blocks pentagastrin-induced gastric acid secretion with an ED50 of 0.01 mg/Kg which is 100-times more potent than L-365, 260. L-740, 093 has a much greater water solubility than L-365, 260 and also has greater than 60-increased activity in the ex vivo brain binding assay, suggesting much greater CNS penetration [56] [57] [58] . The 5-phenyl-1, 4-benzodiazepine analogue, YM022, is also a potent CCKB receptor antagonist in the rat (KY = 0.068 nM) ( Table 2) and has greater than 100-fold selectivity for CCKB over CCKA receptors [47, 59] . Administration of YM022 inhibited pentagastrin-induced gastric acid secretion with an ED50 of 0.0078 gm/Kg and was 540-fold and 129-fold more potent than L-365, 260 (concentration causing half-maximal stimulation
[EC50]-4.23 ,umol/Kg) and CI-988 (EC50 = 1.01 jimol/Kg), respectively [47] . In contrast to L-365, 260, neither YM022 nor CI-988 inhibited histamine or bethachol-stimulated acid secretion, whereas L-365, 260 inhibited both [47] . YM022 orally dose-dependently inhibited acid secretion in pylorus-ligated rats with an ED50 of 0.83 imolKg compared to 1.6 gmol/Kg for famotidine and 10.9 imol/Kg for omeprazole [59] . In rats, YM022 is as potent as famotidine at preventing in rats indomethacin-induced gastric lesions, gastric damage caused by water-immersion and restraint, gastric erosions caused by acidified ethanol and mepirizole-induced duodenal ulcers [59] . Recently, a series of imidazo 1, 4-benzodiazepine analogues have been reported [60] [60] . This compound has similar CNS penetration to L-365, 260 [60] .
The ureido-acetamide analogues RP 69758, RP 72540, and RP 73870 are reported to be potent and selective CCKB receptor antagonists (Table 2, Figure 1 ) [61] [62] [63] . Each of these analogues has greater than 1000-fold selectivity for CCKB receptors over CCKA receptors with RP 73870 having greater than 3000-fold selectivity ( Table 2) . Each of these compounds inhibits pentagastrin-stimulated acid secretion [61, 62] , with RP 73870 causing half-maximal inhibition at 0.05 mg/Kg, i.v.) and was two-fold less potent than famotidine, nine-fold more potent than CI-988, 26-fold more potent than cimetidine and 40-fold more potent than L-365, 260 [62] . RP 73870, at a concentration sufficient to block pentagastrin-stimulated secretion (0.3 mg/Kg, i.v.) has no effect on histamine-stimulated acid secretion, whereas famotidine is equally potent for both [62] . RP 73870 prevents aspirin-induced gastric mucosal injury and is about one-half as potent as cimetidine and 3.5-times as potent as L-365, 260 [62] . RP 73870 also prevents cysteamine-induced duodenal ulceration when given orally and is as potent as omeprazole or famotidine and six-fold more potent than L-365, 260 [62] .
Two other classes of selective CCKB receptor antagonists are described (Table 2 ). Various glutaramic acid derivatives are recently described that have a higher affinity for the CCKB than the CCKA receptor such as CR 2194 (Table 2 ) [64] . From binding studies, CR 2194 only has a 23-fold selectivity [64] , for CCKB receptors, however, it inhibits pentagastrin-stimulated acid secretion in the dog, rat and cat [64] . A number of pyrazolidinone analogues are CCKB selective antagonists [65, 66] . One of the most potent, LY 262, 691 (Table 2) , inhibits CCK-8-induced depolarization in ventromedial hypothalamic neurons and causes a specific decrease in the number of spontaneously active dopamine cells in the central tegmental area, whereas CCKA receptor antagonists have no effect [65, 66] . This latter compound has a 370-fold selectivity for CCKB over CCKA receptors, which is considerably less than the newer benzodiazepine analogues and the ureidoacetamide analogues (Table 2) .
III. CCK RECEPTOR-MEDIATED GASTRIC CHANGES IN WHICH AN;AGONISTS MIGHT BE THERAPEUTICALLY USEFUL
Before the possible therapeutic uses of CCKB receptor antagonists in gastric secretory disorders is considered, it is important to understand what is known about the location and function of CCKB gastrin receptors in the stomach. Limited data are available. Because of the difficulty of purifying each cell type, the exact location of CCKB receptors in the stomach has only been determined in a few cell types. In the stomach, binding and/or functional studies provide evidence for CCKA receptors on human [67] , guinea pig [18, 68] and rat chief cells [17, 69] , whereas both CCKA and CCKB receptors are on guinea pig chief cells [18, 68, 70, 71] (Table 1) . Both CCKA and CCKB receptors exist on canine D cells and regulate somatostatin release [72] . CCKB receptors are found in canine parietal cells [73] , enterochromaffin cells (ECL cells) in dog and rat [74, 75] , and reported to be present in both neurons in the gastric circular muscle layer and in the myenteric plexus in the stomach [76] . Pharmacological studies and binding studies provide evidence for CCKB receptors on gastric smooth muscle [77, 78] (Table 1) .
Evidence exists that activation of CCKB receptors in the stomach can stimulate acid secretion [9, 79, 80] ; release histamine from ECL cells in rat and dog [74, 75, 81] ; stimulate growth of the mucosa of the oxyntic gland area of the stomach increasing mucosal weight, RNA, protein synthesis, and DNA synthesis [9, 79, 82] ; stimulate ECL proliferation [83, 84] , stimulate somatostatin secretion in in vitro preparations [72] ; increase gastric blood flow; increase pepsinogen secretion in some species and alter gastric motility [9, 79, 80] . The responses that are thought physiological are the trophic effects [9, 79] , effects on histamine release, acid secretion and perhaps effects on blood flow. For CCKB receptor antagonists to be useful they need to inhibit one of these functions.
IV. POSSIBLE USE OF CCK RECEPTOR ANTAGONISTS FOR INHIBITINd3ACID SECRETION As reviewed above, it is well established that various classes of the newer CCKB receptor antagonists, as well as L-365, 260, can inhibit acid secretion in animals [47, 57, 59, 61, 62, 85] . The only specific CCKB receptor antagonist examined in humans on acid secretion is L-365, 260 [86] . In this study [86] , in eight healthy male volunteers, oral L-365, 260 caused a dose-dependent inhibition of pentagastrin-stimulated acid secretion, with the 50 mg dose causing half-maximal inhibition. In this study [86] , it was estimated that 50 mg of L-365, 260 caused acid inhibition equal to that caused by five mg of famotidine. It was concluded that the acid inhibitory effect of L-365, 260 was modest and of relatively short duration and, therefore, was unlikely to be clinically useful for this purpose [86] . Furthermore, in many animal studies the CCKB receptor antagonists are much more potent at inhibiting pentagastrin-stimulated acid secretion rather than that caused by histamine or cholinergic agents, demonstrating the specificity of its action for the CCKB receptor [47, 62] . This is in contrast to histamine H2-receptor antagonists or H+-K+ ATPase inhibitors, which inhibit acid secretion stimulated by all secretagogues. Each of these latter compounds inhibit acid secretion by all stimulus: the H+-K+ ATPase inhibitors because of inhibiting a common late step in acid secretion, and histamine H2-receptor antagonists by inhibiting the action of histamine which plays a critical pivotal role in acid secretion mediated by all stimuli [81] . These results suggest that even if a potent, long-acting CCKB antagonist is developed that causes prolonged inhibition of pentagastrin-stimulated acid secretion, because of the specificity of its action for gastrin-stimulated secretion, it is likely to be less useful than the H+-K+ ATPase inhibitors or histamine H2-blockers.
It could be argued that CCKB receptor antagonists might be particularly useful for hypergastrinemic states associated with acid hypersecretion such as Zollinger-Ellison syndrome or antral G cell hyperfunction/hyperplasia [87, 88] . However, the H+-K+ ATPase inhibitors are highly effective in these cases, controlling acid hypersecretion with once or twice a day dosing [88, 89] and for the few patients who can not take these agents, histamine H2-receptor antagonists are effective [88, 89] . It is unlikely CCKB receptor antagonists could improve on the acid-inhibitory effects offered by these agents even in hypergastrinemic states, however it may have a use because of the trophic effects of gastrin in these conditions as discussed below.
V. POSSIBLE USE OF CCK RECEPTOR ANTAGONISTS FOR INHIBITING THE TROPHIC EFFECTS OF HYPERGASTRINEMIA
Recently, there has been increased concern about the consequences of prolonged hypergastrinemia [87, [90] [91] [92] . This has occurred because moderate to severe gastroesophageal reflux disease (GERD) is not uncommon and the H+-K+ ATPase inhibitors are the most effective agents for treatment of GERD of this severity [93] . The chronic use of H+-K+ ATPase inhibitors for GERD and occasionally for peptic disease causes hypergastrinemia in 80 to 100 percent of patients [94, 95] with 30 percent of patients in one study [94] having serum gastrin concentrations more than five-times the upper limit of normal.
It is well established that chronic hypergastrinemia causes an increased rate of the development of gastric carcinoid tumors in animals and man, some of which are malignant [83, 84, 90, 96, 97] . Furthermore, it is controversial whether chronic hypergastrinemia increases the risk of development or growth of colonic neoplasms [90, [98] [99] [100] [101] . [103] and 0.6 percent in another study [87] ). These data suggest the risk of developing significant gastric mucosal changes due to even profound hypergastrinemia is low with existing drugs for at least a five to 10-year period. Because the existing acid antisecretory drugs are so effective, safe, and even with long-term treatment the risk of chronic hypergastrinemia in terms of gastric mucosal changes is low, at present there is little evidence to suggest that the routine use of a CCKB receptor antagonist would be justified. VI. POSSIBLE NONSECRETORY CLINICAL USES OF CCKB RECEPTOR ANTAGONISTS One of the main potential clinical uses of these agents might be in as a drug to prevent panic attacks. These attacks are manifested as episodes of intense anxiety or fear associated with cognitive and somatic symptoms. Repeated occurrence of panic attacks occurs in two percent of the general population [104] . Familial and twin studies suggest in some cases the disorder is inherited [104] . CCKB receptor agonists can precipitate these attacks and CCKB receptor antagonists can prevent the attacks [104] [105] [106] . However, in a recent placebo-controlled trial [40, 43] , 88 patients with panic attacks were treated for six weeks, with placebo or the CCKB receptor antagonist, L-365, 260 (30 mg, four times a day), and the results demonstrated no difference in the occurrence of the panic attacks for the two groups.
Numerous studies show gastrin can effect GI motility and CCKB receptors are known to be present on smooth muscle cells of the GI tract [77, 79] . Also, gastrin-related peptides have growth effects on a number of different tumors [98, 100, 101] . However, the exact pathogenesis of gastrin in either motility disorders or as an anticancer agent has not been defined, and it remains unclear whether CCKB receptor antagonists could be useful clinically in these disorders.
VII. CONCLUSIONS The recent development of five different classes of CCKB receptor antagonists that have a high selectivity and high affinity for CCKB receptor antagonists will provide important tools that will allow the role of these receptors to be defined in normal physiology and in disease states. Because most non-peptide receptor antagonists of various receptors tend not to have species-related agonist activity seen with some peptide antagonists [38, 40] , these new non-peptide CCKB receptor antagonists should be generally useful because they will likely function as antagonists without agonist activity in man and other species. In which disease states CCKB receptor antagonists may be useful therapeutically is at present unclear. Because a number of classes of potent, orally active, selective inhibitors of acid secretion are currently widely used (histamine H2 receptor antagonists, H+-K+ ATPase inhibitors), and because of the modest effects of CCKB receptor antagonists in inhibition of acid secretion, the CCKB receptor antagonists will unlikely be therapeutically useful in this role. It is more likely they will therapeutically useful for certain CNS actions of CCK such as its ability to induce panic attacks or possibly as an antiproliferative agent.
